Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA® uses complex statistical analysis to determine the likelihood that a fetus is carrying a disorder such as Down’s syndrome or other prenatal genetic abnormalities. Although IONA has entered a competitive and litigious market, it has some advantages, is CE Marked, and was first to win UK NHS contracts. Early signs of commercial traction for IONA were evident in the trading update. Also, a recent court hearing has positive outcomes: amalgamating all the defences against patent infringement brought by Illumina, delaying the potential start of the trial, and joining Premaitha up with Roche.
